Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Nov 1;4(6):427-429.
doi: 10.1158/2643-3230.BCD-23-0157.

Understanding Infection Risk with Anti-BCMA Bispecific Antibodies

Alfred L Garfall  1 , Edward A Stadtmauer  1
Affiliations
Comment

Understanding Infection Risk with Anti-BCMA Bispecific Antibodies

Alfred L Garfall et al. Blood Cancer Discov. .

Abstract

Lancman and colleagues find that infection risk in patients treated with anti-BCMA bispecific antibodies for relapsed/refractory multiple myeloma is associated with severe immunoglobulin deficiency and may be mitigated by immunoglobulin replacement therapy. The study has implications for managing infection risk and raises questions about the optimal duration of treatment with these potent, novel immunotherapies. See related article by Lancman et al., p. 440 (4) .

PubMed Disclaimer

Comment on

References

    1. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. . Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505. - PMC - PubMed
    1. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. . Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023;29:2259–67. - PMC - PubMed
    1. Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. . Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 2022;9:e143–61. - PubMed
    1. Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. . IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov 2023; 4:440–51. - PMC - PubMed
    1. Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D'Souza A, et al. . Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma. JAMA Netw Open 2022;5:e2238961. - PMC - PubMed

Substances